EGFR and non-small cell lung carcinoma: A recent network meta-analysis (NMA) revealed that osimertinib was the best therapeutic agent among five major EGFR TKIs as first-line treatments because it achieved the longest PFS of patients with NSCLC containing EGFR-activating mutations [101].